Hikma adds to stake in Promopharm; gets US appro for argatroban
The Pharma Letter Fast-growing Jordan headquartered Hikma Pharmaceuticals (LSE: HIK) says that it has increased its stake in Morocco-based Promopharm (Societe de Promotion Pharmaceutique du Maghreb) to 94.1%, adding to the 63.6%...
Read More